ReviewGlobal challenges (Hoboken, NJ)2025
Emerging Technologies for Timely Point-of-Care Diagnostics of Skin Cancer.
Review in Global challenges (Hoboken, NJ), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative biomolecular analysis of normal and healed skin tissue from diabetic and non-diabetic rats using Raman spectroscopy.Lasers in medical science · 2026Article
- Emerging Technologies for Timely Point-of-Care Diagnostics of Skin Cancer.Global challenges (Hoboken, NJ) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Skin cancer is a global health crisis and a leading cause of morbidity and mortality worldwide. A leading factor of malignancy remains the UV radiation, driving various biomolecular changes. With shifting population behaviors, deficiency in screening programs and reliance on self-presentation, climate change and the ageing world populace, global incidents have been surging alarmingly. There is an urgent need for new technologies to achieve timely intervention through rapid and accurate diagnostics of skin cancer. Raman spectroscopy has been emerging as a highly promising analytical technology for diagnostic applications, poised to outpace the current costly, invasive and slow procedures, frequently hindered by varying sensitivity, specificity and lack of portability. Herein, complex and intricate progress are overviewed and consolidated across medical and engineering disciplines with a focus on the latest advances in the traditional and emerging skin cancer diagnostics. Methods detecting structural and chemical responses are categorized along with emerging chemo-biophysical sensing techniques. Particular attention is drawn to Raman spectroscopy, as a non-invasive, rapid and accurate sensing of molecular fingerprints in dermatological matrix with an additional focus on artificial intelligence, as a decision support tool collectively, laying the platform toward development and rapid translation of point-of-care diagnostic technologies for skin cancer to real-world applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.